RecruitingPhase 2NCT05740722
Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis
Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis: A Randomised Controlled Trial: The NORSEMAN Study
Sponsor
Haukeland University Hospital
Enrollment
300 participants
Start Date
May 3, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis. The main question it aims to answer is: • Does NR delay disability progression in progressive multiple sclerosis? Participants will be treated with NR or placebo for 30 months,
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria7
- A diagnosis of progressive MS (secondary; SPMS or primary; PPMS) according to the 2013 revisions of clinical course of multiple sclerosis and the 2017 revisions of the McDonald criteria.
- Aged 18-65 years.
- EDSS 3-6.5
- Able to perform T25FW test
- The participant must have documented evidence of disability progression observed during the 24 months before screening.
- With or without a stable disease modifying therapy during the last three months.
- Written informed consent for study participation.
Exclusion Criteria9
- A diagnosis of relapsing MS according to the revisions of the McDonald criteria
- Neoplastic disease at baseline
- Previous history of malignant melanoma or breast cancer
- Stable phase of a progressive disease course
- Pregnancy or lactating female patients
- Dementia or other neurodegenerative disorder at baseline visit
- Comorbidity (psychiatric or somatic) that precludes study participation
- Use of high dose vitamin B3 supplementation within 30 days of enrolment
- Genetically confirmed mitochondrial disease or metabolic disorder
Interventions
DIETARY_SUPPLEMENTNicotinamid riboside
500 mg x 2 po
DIETARY_SUPPLEMENTPlacebo
Placebo tablets
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05740722
Related Trials
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
NCT048734921 location
Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment
NCT067824641 location
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT074776392 locations
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
NCT072071481 location